source
- Genmab reports phase 3 success for Elahere competitor and previews Merus buyout dataGenmab disclosed at the European Society for Medical Oncology meeting that its experimental therapy, positioned as a rival to Elahere, achieved a positive outcome in a phase 3 trial. The result si…
- EQT to acquire Qiagen in €10.8 billion dealEQT, a private‑equity firm, announced it will purchase Dutch molecular diagnostics company Qiagen in a transaction valued at €10.8 billion, including €1.1 billion of net debt. The deal follows a f…